01.01.09
Indication: Endothelial dysfunction
Source: Eur Heart J, November 2008;29(22):2800-7.
Research: Researchers set out to investigate the effect of an oral isoflavone supplement on vascular endothelial function in patients with established cardiovascular disease. As such, they carried out a randomized, double-blinded, placebo-controlled trial on 102 subjects for 12 weeks—isoflavone group: 80 mg per day, n = 50) vs. placebo group (n = 52). The objective was to measure brachial flow-mediated dilatation (FMD) in patients with prior ischemic stroke.
Results: Compared with controls, FMD at 12 weeks was significantly greater in isoflavone-treated patients. Further, isoflavone treatment was independently associated with significantly less impairment of FMD at 12 weeks. The data also showed that the effect of the isoflavone supplement on brachial FMD was inversely related to baseline FMD, suggesting that the vasoprotective effect of the isoflavone supplement was more pronounced in patients with more severe endothelial dysfunction. According to researchers, this study demonstrated that 12-week isoflavone treatment reduced serum hs-C-reactive protein and improved brachial FMD in patients with clinically manifest atherosclerosis, thus reversing their endothelial dysfunction status. As a result, they believe these findings may have important implications for the use of isoflavone treatment for secondary prevention in patients with cardiovascular disease, on top of conventional interventions.
Source: Eur Heart J, November 2008;29(22):2800-7.
Research: Researchers set out to investigate the effect of an oral isoflavone supplement on vascular endothelial function in patients with established cardiovascular disease. As such, they carried out a randomized, double-blinded, placebo-controlled trial on 102 subjects for 12 weeks—isoflavone group: 80 mg per day, n = 50) vs. placebo group (n = 52). The objective was to measure brachial flow-mediated dilatation (FMD) in patients with prior ischemic stroke.
Results: Compared with controls, FMD at 12 weeks was significantly greater in isoflavone-treated patients. Further, isoflavone treatment was independently associated with significantly less impairment of FMD at 12 weeks. The data also showed that the effect of the isoflavone supplement on brachial FMD was inversely related to baseline FMD, suggesting that the vasoprotective effect of the isoflavone supplement was more pronounced in patients with more severe endothelial dysfunction. According to researchers, this study demonstrated that 12-week isoflavone treatment reduced serum hs-C-reactive protein and improved brachial FMD in patients with clinically manifest atherosclerosis, thus reversing their endothelial dysfunction status. As a result, they believe these findings may have important implications for the use of isoflavone treatment for secondary prevention in patients with cardiovascular disease, on top of conventional interventions.